MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021

Rhea-AI Summary

MannKind Corporation (Nasdaq:MNKD) will announce its third quarter financial results on November 9, 2021, at 5:00 PM ET. CEO Michael Castagna and CFO Steven B. Binder will discuss the financial performance and corporate updates during a conference call. The call will be available for live listening on the company’s website, with a replay accessible for 14 days. MannKind specializes in developing inhaled therapeutic products, including Afrezza, the only FDA-approved inhaled ultra rapid-acting mealtime insulin in the U.S. More information can be found on their corporate site.

Positive

• MannKind continues to commercialize Afrezza, expanding availability in the U.S. and Brazil.
• The upcoming Q3 financial results may provide insights into the growth trajectory of Afrezza.

Negative

• None.

WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November 9, 2021.

Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven B. Binder.

Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at Events & Presentations https://investors.mannkindcorp.com/events-and-presentations.  A replay will also be available on MannKind's website for 14 days.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza^® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

MANNKIND CONTACT:
Rose Alinaya, Investor Relations
Phone: (818) 661-5000
Email: ir@mannkindcorp.com

FAQ

When will MannKind Corporation release its Q3 2021 financial results?

MannKind Corporation will release its Q3 2021 financial results on November 9, 2021, at 5:00 PM ET.

Who will present the financial results during the conference call for MannKind?

The financial results will be presented by CEO Michael Castagna and CFO Steven B. Binder.

How can I listen to MannKind's Q3 2021 earnings call?

You can listen to the earnings call live by visiting MannKind's website under Events & Presentations.

What is Afrezza and its significance for MannKind Corporation?

Afrezza is the only FDA-approved inhaled ultra rapid-acting mealtime insulin available in the U.S., marking a significant product for MannKind.

How long will the replay of MannKind's conference call be available?

The replay of the conference call will be available for 14 days on MannKind's website.